GTAM
DAWN

Global Trust Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Global Trust Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$353 – 471
2025
Q3 		$353 Hold
50
– – ﹤0.01% 487
2025
Q2 		$325 Hold
50
– – ﹤0.01% 465
2025
Q1 		$397 Hold
50
– – ﹤0.01% 449
2024
Q4 		$634 Hold
50
– – ﹤0.01% 496
2024
Q3 		$697 Hold
50
– – ﹤0.01% 465
2024
Q2 		$689 Buy
+50
New +$732 ﹤0.01% 442

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Global Trust Asset Management's DAWN Position: Q4 2025 in Review

Global Trust Asset Management sold out of Day One Biopharmaceuticals (DAWN) in Q4 2025, closing a stake of 50 shares — an estimated $353 sold.

Global Trust Asset Management first reported a position in DAWN in Q2 2024 and held it in 6 quarters. The position peaked at $697 in Q3 2024. 183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

  • Global Trust Asset Management reported no remaining Day One Biopharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Global Trust Asset Management sold 50 Day One Biopharmaceuticals shares in Q4 2025, an estimated $353.
  • Global Trust Asset Management first reported a position in Day One Biopharmaceuticals in Q2 2024 and held it in 6 quarters.
  • Global Trust Asset Management's Day One Biopharmaceuticals position peaked at $697 in Q3 2024.
  • 183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on Global Trust Asset Management's 13F filing for Q4 2025, filed 20 Jan 2026.